Drug Uses

Colchicine is used to treat attacks of gout.

How Taken

Take each dose of Colchicine with a full glass of water. You may take this medicine up to once every hour until the pain is relieved, until the maximum amount of medicine has been taken, or until nausea, vomiting, or diarrhea occurs. To prevent an attack from occurring, you may take Colchicine every day or several days a week. Do not take more doses than your doctor prescribed.

Warnings/Precautions

Do not take Colchicine without first talking to your doctor if you are breast-feeding a baby. Talk to your doctor if you are or plan on becoming pregnant as this medicine may have harmful effects on the unborn baby.

Missed Dose

If you miss a dose, use it as soon as you remember. If it is near the time for the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

Possible Side Effects

Some of the side effects that may occur while taking Colchicine include: difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; fever; rash; numbness or tingling.

Storage

Store Colchicine at room temperature away from moisture and heat. Keep out of the reach of children.

Overdose

Symptoms of a colchicine overdose include nausea; vomiting; stomach pain; diarrhea; muscle weakness; burning in your throat, stomach, or skin; difficulty breathing; delirium; and seizures. An overdose of colchicine can result in death. If you suspect an overdose, seek immediate medical attention.

More Information

Tell your doctor and pharmacist about all medicines that you are taking. Colchicine may interact with other drugs.

Disclaimer

This drug information is for your information purposes only, it is not intended that this information covers all uses, directions, drug interactions, precautions, or adverse effects of your medication. This is only general information, and should not be relied on for any purpose. It should not be construed as containing specific instructions for any particular patient. We disclaim all responsibility for the accuracy and reliability of this information, and/or any consequences arising from the use of this information, including damage or adverse consequences to persons or property, however such damages or consequences arise. No warranty, either expressed or implied, is made in regards to this information.

Other info about Colchicine at Wikipedia.org and other resources:

QT interval variability in familial Mediterranean fever: a study in colchicine-responsive and colchicine-resistant patients
In conclusion, patients with FMF who are continuously treated with colchicine and have not developed amyloidosis, regardless of their clinical response, have normal QT variability parameters, indicating normal repolarization dynamics and suggesting no increased risk of repolarization-associated cardiac arrhythmias. Content Type Journal ArticleCategory Original ArticlePages 1-5DOI 10.1007/s10067-011-1926-8Authors Udi Nussinovitch, Israel Naval Medical Institute, IDF Medical Corps, Haifa, Israel 31080Keren Kaminer, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelMoshe Nussinovitch, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelBenjamin Volovitz, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelMerav Lidar, Sackler Faculty of Me...

Discovery of small molecule inhibitors that interact with γ‐tubulin
We present experimental evidence that colchicine and combretastatin A‐4 bind to γ‐tubulin, which are to our knowledge the first drug‐like compounds known to interact with γ‐tubulin. Molecular dynamics (MD) simulations and docking studies were used to analyze the hypothesized γ‐tubulin binding domain of these compounds. The suitability of the potential binding modes were evaluated, and suggest the subsequent rational design of novel targeted inhibitors of γ‐tubulin.© 2012 John Wiley & Sons A/S (Source: Chemical Biology and Drug Design)

Mesangial proliferative glomerulonephritis in familial Mediterranean fever patient with E148Q mutation: the first case report
In this report, we present the first case of an FMF patient with heterozygous mutation of E148Q, mesangial proliferative glomerulonephritis, and no amyloidosis. While the association of mutation E148Q with renal involvement is still obscure, colchicine treatment is useful in mesangial proliferative glomerulonephritis with FMF. Content Type Journal ArticleCategory Nephrology – Case ReportPages 1-4DOI 10.1007/s11255-012-0124-1Authors Eray Eroglu, Department of Internal Medicine, Erciyes University Medical School, Kayseri, TurkeyIsmail Kocyigit, Department of Nephrology, Erciyes University Medical School, Kayseri, TurkeyOzturk Ates, Department of Nephrology, Erciyes University Medical School, Kayseri, TurkeyAydin Unal, Department of Nephrology, Erciyes University Medical School, K...

The Effect of Regular Colchicine Treatment on Biomarkers Related with Vascular Injury in Newly Diagnosed Patients with Familial Mediterranean Fever
Abstract  We aimed to evaluate some of the vascular biomarkers in newly diagnosed, colchicine naive familial Mediterranean fever (FMF) patients. Our primary aim was to investigate the effect of regular colchicine treatment on these variables. Twenty-four (12 males [M] and 12 females [F], 33.3 ± 13.4 years) newly diagnosed FMF patients were included in the study. These patients were started on colchicine treatment following the initial assessment and were studied again no earlier than 2 months. Five patients were lost to follow-up, and assessment of the on-treatment patients was performed on the remaining 19 patients (8 M and 11 F, 33.6 ± 11.8 years). There were 19 healthy subjects (11 M and 8 F, 32.2 ± 7.2 years) who served as a control gro...

Gout and Organ Transplantation
Abstract  Acute and chronic gout are common complications following organ transplantation. Risk factors include those shared with the general population (eg, diuretic use) and transplant-specific risk factors (eg, cyclosporine). Clinical features of gout are similar to those seen in the general population, although tophi may be more common. A definitive diagnosis requires demonstration of monosodium urate crystals within synovial fluid or tophi. Treatment is often empiric, although a poor response should prompt joint aspiration to exclude septic arthritis. Corticosteroids are commonly used to treat acute gout due to the adverse profile and drug interactions with NSAIDs and colchicine. Sustained reduction of serum urate (≤6 mg/dL) is critical in long-term management. ...